PEAK6 Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
$157K Sell
6,800
-19,000
-74% -$452K ﹤0.01% 3489
2018
Q1
$635K Sell
25,800
-50,000
-66% -$1.31M ﹤0.01% 2362
2017
Q4
$2.03M Buy
75,800
+72,400
+2,129% +$1.84M 0.01% 1391
2017
Q3
$82K Sell
3,400
-29,600
-90% -$669K ﹤0.01% 3844
2017
Q2
$708K Sell
33,000
-1,200
-4% -$24.2K ﹤0.01% 2217
2017
Q1
$586K Sell
34,200
-14,400
-30% -$251K ﹤0.01% 2127
2016
Q4
$871K Sell
48,600
-111,600
-70% -$2.02M 0.01% 1997
2016
Q3
$3.33M Buy
160,200
+105,800
+194% +$2.62M 0.02% 939
2016
Q2
$1.46M Buy
+54,400
New +$1.49M 0.01% 1487
2016
Q1
Sell
-26,400
Closed -$767K 4845
2015
Q4
$767K Buy
26,400
+15,000
+132% +$415K 0.01% 2184
2015
Q3
$309K Buy
11,400
+400
+4% +$11.3K ﹤0.01% 3344
2015
Q2
$301K Sell
11,000
-23,200
-68% -$652K ﹤0.01% 3314
2015
Q1
$913K Buy
34,200
+18,200
+114% +$419K 0.01% 1965
2014
Q4
$339K Buy
+16,000
New +$357K ﹤0.01% 2910
2014
Q2
Sell
-101,600
Closed -$2.32M 4972
2014
Q1
$2.32M Buy
101,600
+71,600
+239% +$1.53M 0.02% 1161
2013
Q4
$554K Sell
30,000
-620,000
-95% -$10.8M ﹤0.01% 2575
2013
Q3
$5.51M Sell
650,000
-44,000
-6% -$740K 0.04% 683
2013
Q2
$10.8K Buy
+694,000
New +$11.6M 0.04% 284

Other funds holding NVO

PEAK6 Group's NVO Position: Q2 2018 in Review

PEAK6 Group sold out of Novo Nordisk (NVO) in Q2 2018, closing a stake of 19,544 shares — an estimated $464K sold.

PEAK6 Group first reported a position in NVO in Q2 2013 and held it in 7 quarters. The position peaked at $2.22M in Q1 2016. 537 funds tracked by Wall St. Rank hold NVO as of Q2 2018.

  • PEAK6 Group reported no remaining Novo Nordisk position as of Q2 2018 after selling out during the quarter.
  • PEAK6 Group sold 19,544 Novo Nordisk shares in Q2 2018, an estimated $464K.
  • PEAK6 Group first reported a position in Novo Nordisk in Q2 2013 and held it in 7 quarters.
  • PEAK6 Group's Novo Nordisk position peaked at $2.22M in Q1 2016.
  • 537 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.